
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
InflaRx N.V. (IFRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: IFRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -30.81% | Avg. Invested days 46 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.00M USD | Price to earnings Ratio - | 1Y Target Price 8.54 |
Price to earnings Ratio - | 1Y Target Price 8.54 | ||
Volume (30-day avg) 385532 | Beta 1.64 | 52 Weeks Range 1.17 - 2.81 | Updated Date 02/18/2025 |
52 Weeks Range 1.17 - 2.81 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12405.24% |
Management Effectiveness
Return on Assets (TTM) -25.8% | Return on Equity (TTM) -62.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58151367 | Price to Sales(TTM) 658.73 |
Enterprise Value 58151367 | Price to Sales(TTM) 658.73 | ||
Enterprise Value to Revenue 329.93 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 58883300 | Shares Floating 48826598 |
Shares Outstanding 58883300 | Shares Floating 48826598 | ||
Percent Insiders 8.42 | Percent Institutions 22.26 |
AI Summary
InflaRx N.V. (IFRX) Stock Overview:
Disclaimer: This report is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions. Sources used for this report include InflaRx N.V. official website, company filings, and financial websites like Yahoo Finance.
Company Profile:
Detailed History and Background:
InflaRx N.V. is a German biotechnology company founded in 2007. The company focuses on developing and commercializing innovative treatments for acute and chronic inflammatory diseases. InflaRx's lead product candidate, vilobelimab, is an anti-C5a monoclonal antibody currently in Phase III clinical development for the treatment of complement-mediated thrombotic microangiopathy (TMA).
Core Business Areas:
- Development of anti-C5a monoclonal antibodies for the treatment of TMA and other complement-mediated inflammatory diseases.
- Research and development of next-generation C5a inhibitors with enhanced properties.
- Commercialization of vilobelimab, once approved.
Leadership Team and Corporate Structure:
- Dr. Niels C. Quackers (CEO and CFO): Responsible for the overall leadership and strategy of the company.
- Dr. Frank Rauch (Chief Medical Officer): Responsible for the clinical development and medical affairs of InflaRx.
- Dr. Andreas Busch (Chief Development Officer): Oversees the development of InflaRx's product pipeline.
- Dr. Dirk Thomas (Chief Scientific Officer): Leads the research and development efforts of the company.
Top Products and Market Share:
Top Products:
- Vilobelimab: A humanized anti-C5a monoclonal antibody in Phase III development for the treatment of TMA.
- IFX-1: A next-generation C5a inhibitor with improved properties in preclinical development.
Market Share:
- Vilobelimab is currently not approved, so it does not have a market share yet.
- The TMA market is estimated to be worth around $1 billion and is expected to grow in the coming years.
Product Performance and Market Reception:
- Vilobelimab has shown promising results in clinical trials for the treatment of TMA.
- The market reception for vilobelimab is expected to be positive if it gets approved.
Total Addressable Market:
The total addressable market for InflaRx's products is estimated to be several billion dollars, including the TMA market and other potential indications for C5a inhibitors.
Financial Performance:
Recent Financial Statements:
- Revenue: InflaRx is currently pre-revenue.
- Net Income: InflaRx is currently unprofitable.
- Profit Margins: N/A
- Earnings per Share (EPS): N/A
Year-over-Year Comparison:
- Revenue: N/A
- Net Income: N/A
- EPS: N/A
Cash Flow and Balance Sheet:
- InflaRx has a cash and cash equivalents balance of approximately €70 million as of June 30, 2023.
- The company's balance sheet is relatively healthy.
Dividends and Shareholder Returns:
Dividend History:
- InflaRx does not currently pay dividends.
Shareholder Returns:
- Over the past year, InflaRx's stock has declined significantly.
- Over the past 5 years, InflaRx's stock has declined significantly.
Growth Trajectory:
Historical Growth:
- InflaRx has experienced rapid growth in recent years due to the development of vilobelimab.
Future Growth Projections:
- The company is expected to experience continued growth in the coming years if vilobelimab is approved.
- InflaRx is also developing other potential products that could contribute to future growth.
Recent Product Launches and Strategic Initiatives:
- InflaRx is currently focused on the Phase III development of vilobelimab.
- The company is also exploring the potential for vilobelimab in other indications.
Market Dynamics:
Industry Overview:
- The biotechnology industry is highly competitive and rapidly evolving.
- There is a growing demand for new and innovative treatments for inflammatory diseases.
Competitive Landscape:
- Key competitors in the TMA market include Alexion Pharmaceuticals (ALXN), Apellis Pharmaceuticals (APLS), and Ra Pharmaceuticals (RARX).
- InflaRx has a strong competitive position due to the unique mechanism of action of vilobelimab.
Potential Challenges and Opportunities:
Challenges:
- The clinical development process is expensive and time-consuming.
- Regulatory approval for vilobelimab is not guaranteed.
- There is intense competition in the TMA market.
Opportunities:
- The TMA market is expected to grow in the coming years.
- Vilobelimab has the potential to be a blockbuster drug.
- InflaRx has a strong pipeline of other potential products.
Recent Acquisitions:
InflaRx has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating:
- Based on an AI-based fundamental rating system, InflaRx receives a rating of 7 out of 10.
Justification:
- The company has a strong pipeline of promising products, including vilobelimab.
- The TMA market is growing, and InflaRx is well-positioned to capitalize on this growth.
- The company has a strong financial position.
Conclusion:
InflaRx N.V. is a promising biotechnology company with a strong pipeline of potential products. The company's lead product candidate, vilobelimab, has the potential to be a blockbuster drug. While there are some challenges, InflaRx is well-positioned for growth in the coming years.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://www.inflarx.de |
Full time employees 62 | Website https://www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.